AstraZeneca Teams Up with AI Firm to Develop Cancer Drug

The offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, England, on July 21, 2020. (Paul Ellis/AFP)
The offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, England, on July 21, 2020. (Paul Ellis/AFP)
TT
20

AstraZeneca Teams Up with AI Firm to Develop Cancer Drug

The offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, England, on July 21, 2020. (Paul Ellis/AFP)
The offices of British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca PLC in Macclesfield, England, on July 21, 2020. (Paul Ellis/AFP)

Anglo-Swedish drug maker AstraZeneca has signed a deal worth up to $247 million with US artificial intelligence (AI) biologics firm Absci to design an antibody to fight cancer, the Financial Times reported on Sunday.

The collaboration aims to harness Absci's AI technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca, the report said. It did not say what kind of cancer they plan to target.

Absci and AstraZeneca did not immediately respond to a Reuters requests for comment.

The deal includes an upfront fee for Absci, research and development funding and milestone payments, as well as royalties on any product sales, the newspaper said.

Sean McClain, Absci’s founder and chief executive, was quoted as saying the application of engineering principles to drug discovery improved the potential of success and reduced time spent in development.

Absci applies generative artificial intelligence to design optimal drug candidates based on target affinity, safety, manufacturability and other traits.



Götz Valien: The Last Dinosaur in the Movie Poster Industry

Götz Valien (Getty)
Götz Valien (Getty)
TT
20

Götz Valien: The Last Dinosaur in the Movie Poster Industry

Götz Valien (Getty)
Götz Valien (Getty)

In a digital age, Götz Valien is Berlin’s last movie poster artist, producing giant hand-painted film adverts.

For more than three decades, Austrian-born Valien, 65, earns a modest living producing film posters to hang at the city’s most beloved historic cinemas, a craft he says will probably die with him, at least in western Europe.

He adds a distinctive pop art flourish to each image coupled with the beauty of imperfection, part of the reason he has managed to extend his career well into the 21st century, according to an article published by The Guardian.

“Advertising is about drawing attention and I add the human touch, which is why it works,” he told the newspaper.

Valien’s work plays up the image’s essence: the imposing bow of a ship, the haunting eyes of a screen siren, a mysterious smile. He jokingly calls himself a Kinosaurier – a play on the German words for cinema and dinosaur.

His nearly-7x9-meter canvases long-graced the “film palaces” of the German capital, including the majestic Delphi in the west and the socialist modernist masterpiece Kino International on Karl Marx Allee in the east.

But the former’s adverts finally went digital in 2024, while the latter is closed for a years-long, top-to-bottom revamp. Dozens of independent cinemas among his clients have simply gone out of business.

The century-old Filmtheater am Friedrichshain (FaF) is the last movie theater in Berlin still employing Valien to tout its new releases, with his large-format posters covering its facade and interior walls around the ticket-and-popcorn counter.

Movie posters have existed as long as the nearly 130-year-old film industry.

But these days, few releases stay long enough in cinemas to justify bespoke art to advertise them, communications studies professor Patrick Rössler of the University of Erfurt, who has studied the history of film posters, told local media. And most independent cinemas don’t have the profit margins to afford them, even at what Valien calls his bargain-basement prices.